Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 oct. 2024 07h01 HE | Source: Travere Therapeutics, Inc.

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.
07 sept. 2023 04h25 HE | Source: Curium

Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer

PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
16 déc. 2020 03h00 HE | Source: Esperion Therapeutics, Inc.

First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland

- NILEMDO® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and...